与奥沙利铂相关的伴有细胞因子风暴的特异质反应。
Idiosyncratic Reaction with Cytokine Storm Associated with Oxaliplatin.
作者信息
Dembla Vikas
机构信息
Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center ; Hematology-Oncology, Overton Brooks VA Medical Center.
出版信息
Cureus. 2016 May 19;8(5):e615. doi: 10.7759/cureus.615.
Abstract
Oxaliplatin or irinotecan with 5-fluorouracil form the chemotherapy backbone of any systemic treatment of colorectal cancer. We successfully treated an idiosyncratic reaction to oxaliplatin consisting of severe chills, vomiting, diarrhea, and fever in a patient with metastatic colon cancer.
摘要
奥沙利铂或伊立替康联合5-氟尿嘧啶构成了任何结直肠癌全身治疗的化疗基础。我们成功治疗了一名转移性结肠癌患者对奥沙利铂的特异质性反应，该反应表现为严重寒战、呕吐、腹泻和发热。
相似文献
1
Idiosyncratic Reaction with Cytokine Storm Associated with Oxaliplatin.
Cureus. 2016 May 19;8(5):e615. doi: 10.7759/cureus.615.
2
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Jpn J Clin Oncol. 2007 Sep;37(9):686-91. doi: 10.1093/jjco/hym091. Epub 2007 Aug 24.
3
Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Clin Colorectal Cancer. 2004 May;4(1):46-50. doi: 10.3816/ccc.2004.n.009.
4
Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients.
J Biol Regul Homeost Agents. 2002 Apr-Jun;16(2):105-9.
5
Idiosyncratic reaction after oxaliplatin infusion.
Ann Oncol. 2001 Jan;12(1):132-3. doi: 10.1023/a:1008366223918.
6
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
J Clin Oncol. 2001 Nov 15;19(22):4195-201. doi: 10.1200/JCO.2001.19.22.4195.
7
Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
Anticancer Drugs. 2000 Apr;11(4):263-8. doi: 10.1097/00001813-200004000-00006.
8
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
Ann Oncol. 2004 Jul;15(7):1018-24. doi: 10.1093/annonc/mdh259.
9
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.
Ann Oncol. 2007 Dec;18(12):2000-5. doi: 10.1093/annonc/mdm379. Epub 2007 Sep 4.
10
Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
Oncology. 2004;66(2):132-7. doi: 10.1159/000077439.
本文引用的文献
1
Carboplatin hypersensitivity in relapsed ovarian carcinoma: A therapeutic challenge.
Indian J Med Paediatr Oncol. 2014 Jan;35(1):17-20. doi: 10.4103/0971-5851.133705.
2
Hypersensitivity reactions to oxaliplatin.
Cancer Res Treat. 2006 Dec;38(4):240-1. doi: 10.4143/crt.2006.38.4.240. Epub 2006 Dec 31.
3
Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.
Oncology. 2009;76(4):231-8. doi: 10.1159/000205263. Epub 2009 Feb 25.
4
Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
Clin Ther. 2008 Jun;30(6):1160-5. doi: 10.1016/j.clinthera.2008.06.007.
5
Adverse drug reactions: types and treatment options.
Am Fam Physician. 2003 Nov 1;68(9):1781-90.
6
Hypersensitivity and idiosyncratic reactions to oxaliplatin.
Cancer. 2003 May 1;97(9):2301-7. doi: 10.1002/cncr.11379.
7
Clinical pharmacokinetics of oxaliplatin: a critical review.
Clin Cancer Res. 2000 Apr;6(4):1205-18.
Zotero 插件